Kelowna, British Columbia — December 23, 2025 — Leads & Copy —Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) announced final primary and major secondary efficacy endpoint results from its Phase 1b, 12-week chronic study GLP-1-H24-4, which focused on DehydraTECH study arms relative to the Rybelsus control study arm.
The study, conducted in Australia, revealed that DehydraTECH-semaglutide reduced overall side effects by 48% and gastrointestinal side effects by 55% compared to Rybelsus. Richard Christopher, CEO of Lexaria, expressed satisfaction with the study’s success in achieving its primary endpoint and demonstrating superiority in reducing unwanted side effects.
According to the company, all four DehydraTECH test articles appeared safe and well-tolerated after the 12-week treatment and 4-week follow-up. Each of the DehydraTECH arms had lower rates of overall treatment emergent adverse events and gastrointestinal adverse events compared to the Rybelsus control arm.
Specifically, DehydraTECH-semaglutide was the top performer in total adverse event reductions, with a 47.9% reduction compared to Rybelsus. The study also found a statistically significant 54.9% reduction in gastrointestinal adverse events from DehydraTECH-semaglutide versus Rybelsus.
Assessments of glycated haemoglobin (HbA1c) and body weight, major secondary efficacy endpoints, showed that the DehydraTECH-semaglutide formulation performed comparably to Rybelsus in HbA1c reduction. Bodyweight reduction performance was improved for the Rybelsus control arm versus all DehydraTECH arms. A comparison to published Rybelsus bodyweight reduction performance levels in Novo Nordisk’s Pioneer 1 phase 3a randomized study revealed much lower bodyweight reduction performance which was comparable to that achieved with DHT-semaglutide in the current Study.
Based on the study’s findings, Lexaria considers the DehydraTECH-semaglutide test article most worthy of continued investigation. The company intends to consider its options to perform prospective follow on human clinical testing with a DehydraTECH + SNAC + semaglutide composition compared to Rybelsus. Lexaria has a Material Transfer Agreement with a pharmaceutical company and will relay the dataset to them for review.
Lexaria also announced that it has raised a gross total of $7.5 million over two transactions. The financings allow the company to fund prospective new development opportunities for the entirety of calendar 2026, the details of which are in the process of being finalized and will be forthcoming in due course. Deployment of these funds may include, but not be limited to, progressing its prospective further human clinical testing upon DehydraTECH + SNAC + semaglutide as noted above, as well as, supporting other complementary research and development program work in the Glucagon-Like Peptide-1 (“GLP-1”) sector.
Study GLP-1-H24-4 investigated 126 overweight, obese, pre-diabetic and/or type-2 diabetic human volunteers/patients. The primary endpoint in this study was to assess impacts upon safety and tolerability based on the incidence of treatment emergent adverse events. This Study initially included three DehydraTECH arms testing DehydraTECH-CBD, DehydraTECH-semaglutide and a combination of DehydraTECH-CBD with DehydraTECH-semaglutide. Performance across these three initial study arms was monitored compared to commercially available Rybelsus as the Study positive control group.
In an attempt to accommodate the large amount of data captured in study GLP-1-H24-4, additional non-primary (secondary/exploratory) endpoint results are expected to be released next week.
Investor Contact: George Jurcic – Head of Investor Relations, ir@lexariabioscience.com, Phone: 250-765-6424, ext 202
Source: Lexaria Bioscience Corp.
